Wockhardt has received its board’s approval to raise up to Rs 2200 crore through equity and debt instruments. The company has decided to raise up to Rs 1200 crore through issuance of non-convertible debentures (NCDs) on a private placement basis and up to Rs 1000 crore through equity instruments, including qualified institutional placement (QIP) of shares.
Wockhardt is one of the few companies with end to end integrated capabilities for its products, starting with the manufacture of the oral and sterile API’s, the dose forms and marketing through wholly owned subsidiary in the US, enabling the company to capture maximum value.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1672.50 |
| Dr. Reddys Lab | 1236.80 |
| Cipla | 1234.00 |
| Zydus Lifesciences | 938.50 |
| Lupin | 2323.80 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: